<?xml version="1.0" encoding="UTF-8"?>
<p>The new combination of AZT, together with other drug classes like the non-nucleoside reverse transcriptase inhibitor (NNRTI), Efavirenz (EFV), has reported promising results on multidrug-resistant HIV-1 patients [
 <xref rid="B37-viruses-12-01058" ref-type="bibr">37</xref>]. To date, studies are continuously evaluating the potential of drugs to repurpose for HIV as it is often regarded as an incurable chronic disease [
 <xref rid="B77-viruses-12-01058" ref-type="bibr">77</xref>,
 <xref rid="B78-viruses-12-01058" ref-type="bibr">78</xref>]. For example, it was discovered that two current drugs, iodixanol, and sirolimus work synergistically at specific concentrations for HIV treatment via molecular docking simulations [
 <xref rid="B78-viruses-12-01058" ref-type="bibr">78</xref>]. 
</p>
